Matching articles for "osimertinib"
Issue 1715 · November 11, 2024 Free
In Brief: A New Non-Small Cell Lung Cancer Indication for Osimertinib (Tagrisso) (online only)

The oral kinase inhibitor osimertinib ( Tagrisso – AstraZeneca), which has been available for years for treatment of non-small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR)…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):e190-1 doi:10.58347/tml.2024.1715h
The oral kinase inhibitor osimertinib ( Tagrisso – AstraZeneca), which has been available for years for treatment of non-small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, has now been approved for treatment of unresectable stage III EGFR-mutated NSCLC. About 20-30% of patients with NSCLC have locally advanced stage III NSCLC, and 60-90% of these patients have unresectable disease. Osimertinib is the first targeted therapy to be approved for the new indication.
Issue 1714 · October 28, 2024
Lazertinib (Lazcluze) for Non-Small Cell Lung Cancer (online only)

Lazertinib ( Lazcluze – Janssen Biotech), an oral kinase inhibitor, has been approved by the FDA for use in combination with the EGFR-MET bispecific antibody amivantamab (Rybrevant) for first-line treatment…

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):e176-7 doi:10.58347/tml.2024.1714g
Lazertinib ( Lazcluze – Janssen Biotech), an oral kinase inhibitor, has been approved by the FDA for use in combination with the EGFR-MET bispecific antibody amivantamab (Rybrevant) for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. This is the first approval for Lazcluze ; amivantamab was previously approved for use alone and in combination with carboplatin and pemetrexed for treatment of NSCLC with EGFR exon 20 insertion mutations.
Issue 1682 · August 7, 2023
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)

The FDA has approved osimertinib ( Tagrisso – AstraZeneca), an oral kinase inhibitor, for adjuvant treatment of non-small cell lung cancer (NSCLC) after tumor resection in adults who have epidermal growth…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e131-2 doi:10.58347/tml.2023.1682c
The FDA has approved osimertinib ( Tagrisso – AstraZeneca), an oral kinase inhibitor, for adjuvant treatment of non-small cell lung cancer (NSCLC) after tumor resection in adults who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Osimertinib is the first targeted therapy to be approved in the US for this indication. The drug was previously approved for first-line treatment of adults with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations and for treatment of EGFR T790M mutation-positive NSCLC in adults whose disease progressed on or after EGFR tyrosine kinase inhibitor therapy.
Issue 1513 · January 30, 2017
Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC

The FDA has approved the immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell…

Med Lett Drugs Ther. 2017 Jan 30; 59(1513):22-3
The FDA has approved the immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations. About 25% of patients with advanced NSCLC have tumors with high levels of PD-L1 expression (PD-L1 expressed on ≥50% of tumor cells). Pembrolizumab was approved earlier for treatment of metastatic NSCLC with PD-L1 expression ≥1% that progressed on or after platinum-based chemotherapy.